. Author manuscript; available in PMC: 2012 Jun 15.

Published in final edited form as: Toxicol Appl Pharmacol. 2011 Apr 12;253(3):244–252. doi: 10.1016/j.taap.2011.03.025

Table 1.

Sequences of morpholino antisense oligonucleotides against translation of AHR2, CYP1C1 and CYP1C2.

Target	Concentration	Sequence
AHR2-MO	50 μM	5'-TGTACCGATACCCGCCGACATGGTT-3'
5mis-AHR2-MO	50 μM	5'-TcTAgCGATACCCcCCGAgATGcTT-3'
CYP1C1-MO1	50 μM	5'-TTCTTCCCAAAGTGTATTCTTCTGA-3'
5mis-CYP1C1-MO1	50 μM	5'-TTCTTCCgAAAcTcTATTCTTgTcA-3'
CYP1C1-MO2	25 μM	5'-TCTTCAGTCCAAACTCAGCCTCCAT-3'
5mis-CYP1C1-MO2	25 μM	5'-TCTTgAcTCgAAACTgAcCCTCCAT-3'
CYP1C2-MO1	50 μM	5'-TAACTCCCCATCTTAAAAACGAGCC-3'
5mis-CYP1C2-MO1	50 μM	5'-ATtACTgCCCATgTTAAAAgGAcCC-3'
CYP1C2-MO2	25 μM	5'-GAACTCTGAATCCGACTGCGCCATG-3'
5mis-CYP1C2-MO2	25 μM	5'-GAAgTCTcAATCCcACcCGCgATG-3'

Modified nucleotides are indicated by small letters as for 5 nucleotide-mismatch negative controls.